Jakob R Passweg

Head

University Hospital Basel

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Jakob R. Passweg is the Head at Basel University Hospital in Switzerland. His research focuses on hematopoietic cell transplantation, with recent articles exploring topics such as conditioning intensity in myelodysplastic patients, the impact of ABO compatibility on transplantation outcomes, and the effects of COVID-19 isolation measures in transplant units. He is actively involved in studies that assess therapies and complications in the context of blood and marrow transplantation.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (4)

Stefanie Hayoz

Head of Statistics

SWITZERLAND

View details

Ibrahim Yakoub-Agha

Professeur des Universités - Praticien Hospitalier

Centre Hospitalier Régional Universitaire de Lille

FRANCE

View details

Emanuele Angelucci

Hematology and Transpalnt Center Head

Ospedale Policlinico San Martino

ITALY

View details

Cristina CASTILLA LLORENTE

Institut Gustave Roussy

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jakob R Passweg

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature.

Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party.

The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT.

Isolation measures during the COVID-19 pandemic in transplant units may decrease respiratory infection rates and improve non-relapse mortality

Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT

Busulfan Once Versus Four Times Daily: Impact on Pharmacokinetics, Organ Toxicities and Survival After Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT

The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT

Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT

Collaborators (4)

Stefanie Hayoz

Ibrahim Yakoub-Agha

Emanuele Angelucci

Cristina CASTILLA LLORENTE

Make your next move.